Immunotoxicology Specialty Section Newsletter · Immunotoxicology Specialty Section Newsletter President Dr. Kenneth L. Hastings Vice President Dr. Mitchell D. Cohen Vice President-Elect

Immunotoxicology Specialty Section Newsletter

PresidentDr. Kenneth L. Hastings

Vice PresidentDr. Mitchell D. Cohen

Vice President-ElectDr. Stephen B. Pruett

Secretary-TreasurerDr. Helen V. Ratajczak

Past PresidentDr. Robert W. Luebke

Senior CouncilorDr. Jeanine L. Bussiere

CouncilorsDr. Gregory S. LadicsDr. Michael McCabe

Student RepresentativeJamie DeWitt

P r e s i d e n t ’ s M e s s a g e

The Immunotoxicology Specialty SectionNewsletter is published 3 times/year (May,August and November). If you would like toshare a book review, meeting report, interest-ing web site or any other item of interest withmembers of the Specialty Section, please sendit to us by the middle of the month precedingthe planned publication date. All commentson, or suggestions for, the newsletter are welcome.

Helen V. Ratajczak, Ph.D., EditorDepartment of ToxicologyBoehringer Ingelheim Pharmaceuticals, Inc.900 Ridgebury Road, PO Box 368 R9-5Ridgefield, CT 06877Tel. (203) 798-4720 Fax (203) 798-5797

Stephen B. Pruett, Ph.D., Associate Editor Department of Cellular Biology and Anatomy LSU Health Sciences Center 1501 Kings Highway Shreveport, LA 71130 Tel. (318) 675-4386 Fax (318) 675-5889 [email protected]

Typesetting provided by Brenda House.

2005 - 2006Executive Committee

November 2005 1 Immunotoxicology Specialty Section

Ken Hastings

I hope this message finds all in good health and happy at their jobs. Having justmoved to the new FDA building (no, it’s not a superfund site, but the construc-tion workers did dig up a cylinder that once contained phosgene the other day)I’m still working out of boxes for the most part. This will be a short message,but there are a few items I need to bring to your attention.

First: program suggestions. Please start working on them now – and send themto Steve Pruett, the sooner the better. It will be very helpful to the ProgramCommittee if they have proposals to read before going to San Diego, and I wantto continue the ISS tradition of having excellent contributions to the annualmeeting. A few suggestions: try to contact the folks you want as speakers assoon as you can – this will help your proposal(s). Also, it does help to have morethan one SS sponsor, and lining them up before San Diego also helps. DoriGermolec serves on the SOT Program Committee and Mike Holsapple is onCouncil: both can provide sage advice, as well as past officers.

Second: we will have a ballot for officers sent out before San Diego. You willbe voting for Vice President-elect and Councilor and I hope to have the slatecompleted very soon.

Third, please consider nominating colleagues for the various awards given bythe SS. These include Career Achievement, Young Investigator, and Best Paper. Iwant to draw your attention specifically to the Young Investigator award: wehave not had great response to this award, and I know there are plenty of Itoxersout there who are truly deserving.

Now, for a short travelogue. In September, my wife (Hanan Ghantous) and Itraveled to Shenyang, China to give talks at the Chinese Society of Toxicologymeeting. In addition, we gave lectures at the Nanjing College of Medicine. Itwas a truly enlightening trip. A few observations: despite what you may haveread, the Chinese are well aware of the pollution problems that have resultedfrom a rapidly expanding economy. One result is that toxicology is a hot topic inChina: they may be well-behind EPA and other national environmental agenciesin having regulatory muscle, but that may not last. Simply put, it is difficult toimagine that the Chinese government would be putting as much effort into envi-ronmental sciences if there’s no intent to use the data to inform some pollutionmitigation process. How all of this will develop isn’t clear, but I was pleasantlysurprised at both the apparent level of activity in toxicology as well as the quali-ty of science. Yes, they have a lot of catching up to do, but toxicology is alive

IMPORTANTDEADLINES

Awards Submissions . . . . . . . . . . . . . . . . . . . . See page 3


Program CommitteeReportSubmitted by Steve Pruett

The Immunotoxicology SpecialtySection has traditionally sponsoredexcellent and well-attended programsat the Annual Meeting. However, weare totally dependent on our member-ship to keep this tradition alive. Mostof us have a particular issue or area ofimmunotoxicology that we feeldeserves more attention. Here is yourchance to actually do something aboutit! We are now seeking program pro-posals for the 2007 meeting inCharlotte. Please put a program pro-posal together and submit it to me([email protected]) by November31, 2005. Please follow the guidelinesthat you will find online(http://www.toxicology.org/ai/fa/form-sapps.asp; ignore the date, which is forlast year’s deadline). See the previousImmunotoxicology Specialty SectionNewsletter for a list of previous programs sponsored by our specialtysection.

Student RepresentativeSubmitted by Jamie DeWitt

Greetings students and post-docs! It’shard to believe that SOT is only a fewmonths away and that time to work onour posters and talks is quickly short-ening. As you think about your sched-ule for the national meeting, pleasetake the opportunity to get involvedwith the ISS. As a student, you mayserve on any of the committees anddoing so will give you the chancemake new contacts and to see howSOT hosts so many programs andevents. For example, as a member ofthe ISS Program Committee, I amexpected to put together a proposal foran ISS-sponsored workshop, sympo-sium, or continuing education coursefor SOT 2007. Not only do I have to

come up with a topic that hasn’t beenaddressed by the ISS in recent years, Ineed to contact potential speakers. Thisexperience will introduce me to leadersin immunotoxicology and may give methe opportunity to co-chair the programat the 2007 national meeting. Pleaseattend the ISS business meeting/socialhour in San Diego and sign up for acommittee!

As mentioned in the last newsletter, theISS will have two student representa-tives. I will serve as the “senior” repre-sentative until 2007 and the new repre-sentative will be “junior” for his or herfirst year. We will welcome the newrepresentative during the ExecutiveCommittee meeting in San Diego. Wehope to continue to have one post-doc-toral representative and one pre-doctor-al representative. Even though post-and pre-docs have similar needs, theExecutive Committee thought that hav-ing the two viewpoints representedwould better serve student/post-docISS members.

Please be sure to visit the student sec-tion of the SOT web site. The membersof the Student Advisory Committeehave updated the web site and it nowcontains contact information for all ofthe student specialty section represen-tatives and an outline of the functionsof each specialty section. If you’relooking for a second specialty sectionto join, after the ISS of course, youmay want to peruse this updated infor-mation.

**********

I will announce the date, time, andlocation of the SOT 2006 ISS student

mixer in the next newsletter.

**********

If you have any questions or concernsabout how the ISS can best serve youas a student or post-doc in immunotox,please do not hesitate to contact me [email protected].

and well in China. The Chinese alsoseem intent on developing an indige-nous drug industry, and toxicology is amajor part of that effort as well. It is aninteresting thing to see in person, butthe important take home for me wasthe apparent effort not to simply pursuegenerics, but to build an infrastructureto develop novel drug products. Onceagain, how this will play out will beinteresting. One particular note ofinterest is that immunotoxicology isconsidered one of the basic areas ofinterest in toxicology and I had thechance to meet some of the scientistsconducting research in our favoritearea. Here, they need help. As MitchCohen will tell you in his account ofthe Japanese Society ofImmunotoxicology meeting, perhapswe should consider international out-reach. The Chinese are certainly inter-ested, and we should be also.

Finally, as many of you know, ourbeloved colleague Jeff Vos has been inbad health and is at home now. He’snot reading e-mails, but would love tohear from you: please send to him viahis work address and they will makesure he gets your letters:

Joseph G Vos, DVM, PhDNational Institute of

Public Health and EnvironmentLaboratory of Pathology

and ImmunobiologyAntonie Van Leeuwenhoeklaan 9

Bilthoven, 3721 MA THE NETHERLANDS

Well, that’s all from the constructionsite. Hopefully, the phosgene tank willbe the last surprise (but I’m not count-ing on it.) My office telephone numberhas changed: it is now (301) 796-0169. Don’t hesitate to use it – talkingis more fun than working any day.


Awards Submissions

Outstanding Young Immunotoxicologist AwardAn engraved plaque will be awardedto a scientist who has made signifi-cant contributions to the field ofImmunotoxicology. The recipientmust have less than 15 years ofexperience since obtaining this/herhighest earned degree at the timewhen the award is presented. Thenomination should summarize thecontributions of the candidate scientist and should include a cur-riculum vitae and a bibliography.(Exceptions to the 15 year limitationcan be made if careers have beeninterrupted for family or health rea-sons, by clinical practice, etc.Reasons for the exception should bedocumented in the nomination).Decisions will be made by membersof the Awards Committee and theVice President.

The deadline for submission isDecember 8, 2005.

Please submit nominations to:Dr. Mitch CohenEmail: [email protected]

Career Achievement AwardAn engraved plaque will be awardedto a Senior Investigator whose bodyof work represents an outstandingachievement in immunotoxicology.The nominator should provide a dis-cussion of the role that the individ-ual’s work has played in advancingthe field of immunotoxicology. Acurriculum vitae and bibliographyshould also be included. A secondletter of recommendation from

another investigator in the fieldwould be helpful. Nominees areevaluated with respect to the follow-ing criteria:

1) Contribution to the field ofimmunotoxicology - depth andbreadth of scientific contributionsand significance of contributions foradvancing the field. (weighted value= 50%);

2) Major influence in the educa-tion/training/mentorship of youngscientists in the field of immunotox-icology including training in govern-ment, industry, or academia (weight-ed value = 20%);

3) Leadership and service to theimmunotoxicology field includinginvolvement in the Specialty Sectionor other meetings/organizationsrelated to immunotoxicology(weighted value =20%);

4) Influence on regulatory andrisk/safety assessment decisionsrelated to immunotoxicology.(weighted value = 10%).Nominations of unsuccessful candi-dates will be considered for twoadditional years unless the nomina-tion is withdrawn by the sponsor.Final decisions will be made by theNominating Committee (President,last three Past Presidents, and VicePresident-Elect) and the VicePresident.

The deadline for submission isDecember 8, 2005.

Please submit nominations to:Dr. Mitch CohenEmail: [email protected]

Best Immunotoxicology Paper ofthe Year AwardA very lovely engraved plaque willbe awarded to the author(s) of apeer-reviewed paper in the area ofimmunotoxicology. The paper, maybe published in any peer-reviewedjournal, and must have been pub-lished between July 1, 2003 andDecember 31, 2004. The nominationfor this award should provide a fullcitation of the paper and a short dis-cussion of the importance of theresearch to the discipline ofImmunotoxicology.

Authors may not self-nominate theirown papers. Decisions on this awardwill be made by the AwardsCommittee.

The submission deadline isJanuary 31, 2006.

Please submit nominations to theSenior Councilor: Mike McCabe([email protected])


The 12th Annual Meetingof the Japanese Society ofImmunotoxicology (JSIT)was held on September20-21, 2005 at Yayoi Hall(School of AgriculturalSciences) on the HongoCampus of the Universityof Tokyo. The JapaneseSociety of Immuno- toxicology is comprisedof ≈200 scientists work-ing in academia, industry, and govern-ment agencies. At the meeting, theoral presentations covered a wide variety of topics, including:

• Perspectives on an IntegratedUnderstanding of Immunotoxicities

• Prevention Systems inOccupational/EnvironmentalAllergy and Immunotoxicology

• Trends in Nanoparticle Studies ofHealth Effects

• Effects of PM on Immune Systemand Oxidative Stress

• Crosstalk Between IL-4/-13 Signalsand Dioxin

• Effects of Asbestos on HumanImmunocompetent Cells

• In Vitro Skin Sensitization TestUsing THP-1 Cells

• Chemokine Release from MastCells by Environmental Chemicals

• Biomarkers of Mast Cell Activation

• Application of Toxicogenomics forEvaluation of Immunotoxicity ofPollutants

• Bioinformatics and AllergenicityPredictions for Food Safety

• Construction of a Novel AllergenDatabase ADFS

In addition, there were multiple postersessions that covered a gamut of top-ics, including many of the same areasthat were touched upon in the varioussymposia.

Only a very few members of ourSpecialty Section have ever attended,let alone been invited to speak at, pre-vious JSIT meetings. These earlierinvitees were Mike Luster, Jeff Vos,Ian Kimber, and Steve Holladay, Thisyear, the organizing committee, underthe leadership of JSIT President Dr.Motoyasu Ohsawa, extended speakinginvitations to two more members ofIMTOX: myself and Dr. RaymondPieters (Institute for Risk AssessmentSciences [IRAS] at Utrecht Universityin the Netherlands). The topics cov-ered in the respective talks were“Trends in ImmunotoxicologyResearch in the USA“ and“Immunotoxicology of TherapeuticsAssociated with Allergy andAutoimmunity”. The session attendeesgreatly appreciated both lectures andthere were subsequent extensivethoughtful interchanges with the audience each time. In gratitude - andin a very kind gesture, both Ray and Iwere warmly acknowledged at a dinner reception the first night.

Apart from the science matters, infor-mal discussions were undertaken withseveral members of the JSIT

Executive Committee toestablish ways for each ofour Specialty Sections tobecome increasingly inter-active. Potential means tobroaden recognition of theJSIT by IMTOX membersin Europe and NorthAmerica (and vice-versa)were discussed. Theseranged from: helping theJSIT with establishing web

pages in English so that our membersmight be more aware of their annualmeetings; sending the IMTOXNewsletters to all their membersthrough their Secretary; and, placingsome material provided by the JSITinto IMTOX Newsletters during thecourse of each year. Extensive discussions about trying to develop amechanism by which members of therespective Specialty Sections – includ-ing hopefully students/post-docs –could be able to attend each year’srespective meetings also took place.Many of these issues were to be takenup by the IMTOX ExecutiveCommittee in late October/earlyNovember. A follow-up on these issueswill be provided in the February 2006Newsletter (or covered during the Business Meetingin San Diego in March). Suggestionsare always welcome to help in thisnew endeavor; please forward anycomments/suggestions to me [email protected].

REPORT FROM THE 12th ANNUAL MEETING OF THE JAPANESE SOCIETY OF IMMUNOTOXICOLOGY – TOKYO –

SEPTEMBER 20-21, 2005By Mitch Cohen

Faculty positions in Biological SciencesAs part of an ongoing expansion, the Department of BiologicalSciences at Mississippi State University invites applications for mul-tiple tenure-track faculty positions, beginning August 16, 2006. TheDepartment of Biological Sciences is focused on enhancing its inter-national research reputation and expanding the doctoral program.

During this round of recruitment we are specifically interested in the following areas:

ImmunologySuccessful applicants will be encouraged to take advantage of our state-of-the-art infrastructure in proteomics, genomics,and computing capabilities at the MSU campus, including the Life Sciences & Biotechnology Institute(www.mafes.msstate.edu/biotech) and Engineering Research Center (www.erc.msstate.edu). The successful candidateswill be required to develop externally funded research programs and to direct graduate students and will contribute to theteaching mission of the department.

To apply send:

1) CV,2) Reprints of three representative publications,3) A concise statement of current and future research interests (1 page), and4) Identify areas of teaching competence.

Applicants also should arrange for at least three letters of reference to be submitted.

Screening will begin October 31, 2005 and will continue until the positions are filled (Applications are still beingscreened).

Applications should be sent to: Nara Gavini ([email protected]) Head, Department of BiologicalSciences, P.O. Box GY, Mississippi State University, Mississippi State, MS 39762.

Mississippi State University is An Affirmative Action/Equal Opportunity Employer

Global Drug Discovery and Development ServicesWe are searching for candidates for a global drug discovery and development services company located on theEast Coast. Please contact Lee or Amy at AtticusWorks for more information: 866-941-9675, or [email protected].

Scientific Director — Immunology and InflammationAs an experienced biological or medical scientist, your role as the Scientific Director of Immunology and Inflammation isto be the thought leader and company spokesman for all services and information products related to immunological andinflammatory diseases. The Scientific Director must understand the needs of pharmaceutical and biotechnology compa-nies in their mission to discover and develop treatments and diagnostics. Requires a PhD or MD with a minimum of 10years experience in immunology.

Director — ImmunotoxicologyThis position requires someone that can proficiently serve as the Principal Study Director/Toxicologist, who can act as aprofessional resource to other departments, and develops and reviews new procedures, technologies and SOPs as required.This director supervises assigned Study Directors as follows: reviews workload, conducts protocol and report peerreviews, reviews study protocols, approves study data, coordinates training, etc. Requires a Ph.D. degree inPharmacology/Toxicology or related field, or DVM, and at least 5 years relevant experience in contract toxicology;expertise in toxicology, reproductive toxicology, immunology, pharmacology and/or related fields; DABT or workingtoward certification.


POSITIONANNOUNCEMENTS


Compiled by Haley Neff-LaFord.

ANYTIME you have a new publication to report, please sent it to Haley Neff-LaFord: [email protected].

ASTHMA, ALLERGY AND HYPERSENSITIVITY

Burns-Naas L, Lee C, Evering W, Ahern L, Webber S, and Zorbas M. Lack of respiratory and contact sensitizing potential of theintranasal antiviral drug candidate Rupintrivir (AG7088): A weight-of-the-evidence evaluation. J. Immunotoxicol. 2, 123-140,2005.

De Haar C, Hassing I, Bol M, Bleumink R and Pieters R. Ultrafine carbon black particles cause early airway inflammation andhave adjuvant activity in a mouse allergic airway disease model. Toxicol. Sci. 87 (2), 409-418, 2005.

Dong CC, Yin XJ, Ma JYC, Millecchia L, Barger MW, Roberts JR, Zhang XD, Antonini JM and Ma JKH. Exposure of BrownNorway rats to diesel exhaust particles prior to ovalbumin (OVA) sensitization elicits IgE adjuvant activity but attenuates OVA-induced airway inflammation. Toxicol. Sci. 88, 150-160, 2005.

Dong CC, Yin XJ, Ma JYC, Millecchia L, Wu ZX, Barger MW, Roberts JR, Antonini JM, Dey RD and Ma JKH. Effect of dieselexhaust particles on allergic reactions and airway responsiveness in ovalbumin-sensitized Brown Norway rats. Toxicol. Sci. 88,202-212, 2005.

van Wijk F, Hoeks S, Nierkens S, Koppelman SJ, van Kooten P, Boon L, Knippels LMJ, and Pieters R. CTLA-4 signalling regu-lates the intensity of a food allergic response, but is decisive in the induction of sensitization to food antigens. J. Immunol. 174,174-179, 2005.

van Wijk F, Nierkens S, Hassing I, Feijen M, Koppelman SJ, de Jong GA, Pieters R, Knippels LM. The effect of the food matrixon in vivo immune responses to purified peanut allergens. Toxicol. Sci. 86 (2), 333-341, 2005.

ReviewsHourihane JOB and Knulst AC. Thresholds of allergenic proteins in foods. Toxicol. Appl. Pharmacol. 207 (2), (1 Suppl.), 152-156, 2005.

Kimber I and Dearman RJ. What makes a chemical a respiratory sensitizer? Curr. Opin. Allergy and Clin. Immunol. 5, 119-124,2005.

Knippels LMJ and Penninks AH. Recent advances using rodent models for predicting human allergenicity. Toxicol. Appl.Pharmacol. 207 (2), (1 Suppl.), 157-160, 2005.

Ryan CA, Gerberick GF, Gildea LA, Hulette BC, Betts CJ, Cumberbatch M, Dearman RJ and Kimber I. Interactions of contactallergens with dendritic cells: opportunities and challenges for the development of novel approaches to hazard assessment.Toxicol. Sci. 88 (1), 4-11, 2005.

CYTOKINES AND CHEMOKINES

Cumberbatch M, Clelland K, Dearman RJ, and Kimber I. Impact of cutaneous IL-10 on resident epidermal Langerhans cells andthe development of polarized immune responses. J. Immunol. 175, 43-50, 2005.

Ueng TH, Hung CC, Kuo ML, Chan PK, Hu SH, Yang PC and Chang LW. Induction of fibroblast growth factor-9 and inter-leukin-1a gene expression by motorcycle exhaust particulate extracts and benzo[a]pyrene in human lung adenocarcenoma cells.Toxicol. Sci. 87, 483-496, 2005.

Shwe TTW, Yamamoto S, Kakeyama M, Kobayashi T and Fujimaki H. Effect of intratracheal instillation of ultrafine carbonblack on proinflammatory cytokine and chemokine release and mRNA expression in lung and lymph nodes of mice. Toxicol.Appl. Pharmacol. , 209 (1), 51-61, 2005.

R e c e n t I m m u n o t o x i c o l o g y P u b l i c a t i o n s


DEVELOPMENTAL IMMUNOTOXICITY

Besteman EG, Zimmerman KL, and Holladay SD. Tetrachlorodibenzo-p-dioxin (TCDD) inhibits differentiation and increasesapoptotic cell death of precursor T cells in the fetal mouse thymus. J. Immunotoxicol. 2:107-114, 2005.

Guo TL, Auttachoat W and Chi RP. Genistein enhancement of respiratory allegen trimellitic anhydride-induced IgE productionby adult B6C3F1 mice following in utero and postnatal exposure. Toxicol. Sci. 87, 409-418, 2005.

Holsapple MP, Burns-Naas LA, Hastings K, Ladics GS, Lavin AL, Makris S, Yang Y, and Luster M. A Testing Framework forDevelopmental Immunotoxicology (DIT): Roundtable Discussion. Toxicol. Sci. 83(1), 18-24, 2005.

Ladics GS, Chapin RE, Hastings KL, Holsapple MP, Makris SL, Sheets LP, Woolhiser, MR, and Burns-Naas LA. Developmentaltoxicology evaluations – issues with including neurotoxicology and immunotoxicology assessments on reproductive studies.Toxicol. Sci. 88, 24-29, 2005.

EFFECTS: COMPOUNDS

Colosio C, Birindelli S, Corsini E, Galli CL, and Maroni M. Low level exposure to chemicals and immune system. Toxicol.Appl. Pharmacol. 207 (2 Suppl), 320-328, 2005.Corsini E, Birindelli S, Fustinoni S, De Paschale G, Mammone T, Visentin S, Galli CL, Marinovich M, Colosio C.Immunomodulatory effects of the fungicide Mancozeb in agricultural workers. Toxicol. Appl. Pharmacol. 208(2),178-85, 2005.

DeWitt JC, Copeland CB, and Luebke RW. Immune responses in Sprague-Dawley rats exposed to dibutyltin dichloride in drink-ing water as adults. J. Immunotoxicol. 2, 151-160, 2005.

Ezendam J, Kosterman K, Spijkerboer H, Bleumink R, Hassing I, van Rooijen N, Vos JG, and Pieters R. Macrophages areinvolved in hexachlorobenzene-induced adverse immune effects. Toxicol. Appl. Pharmacol. 2005.

Gao J, Voss AA, Pessah IN, Lauer FT, Penning TM and Burchiel SW. Ryanodine receptor-mediated rapid increase in intracellu-lar calcium induced by 7,8-benzo[a]pyrene quinone in human and murine leukocytes. Toxicol. Sci. 87, 419-426, 2005.

Keller JM, McClellan-Green PD, Kucklick JR, Keil DE, and Peden-Adams MM. Effects of organochlorine contaminants on log-gerhead sea turtle immunity: comparison of a correlative field study and in vitro exposure experiments. Environ. HealthPerspect. doi:10.1289/ehp.8143. Online 21 September 2005.

Keller JM, McClellan-Green PD, Lee AM, Arendt MD, Maier PP, Segars AL, Whitaker JD, Keil DE, Peden-Adams MM.Mitogen-induced lymphocyte proliferation in loggerhead sea turtles: comparison of methods and effects of gender, plasmatestosterone concentration, and body condition on immunity. Vet. Immunol. and Immunopathol. 103 (3-4), 269-281, 2005.

Myers LP, Fan R, Zheng Q, and Pruett SB. Sodium methyldithiocarbamate causes thymic atrophy by an indirect mechanism ofcorticosterone up-regulation. J. Immunotoxicol. 2:97-106, 2005.

Nierkens S, Aalbers M, Bol M, Bleumink R, van Kooten P, Boon L, Pieters R. Differential requirement for CD28/CTLA-4-CD80/CD86 interactions in drug-induced type 1 and type 2 immune responses to trinitrophenyl-ovalbumin. J. Immunol. 175 (6),3707-3714, 2005.

Parthasarathy NJ. S. Kumar S and Sheela Devi R. Effect of methanol intoxication on rat neutrophil functions. J. Immunotoxicol.2:115-121, 2005.

Sakurai T, Ohta T, and Fujiwara K. Inorganic arsenite alters macrophage generation from human peripheral blood monocytes.Toxicol. Appl. Pharmacol. 203 (2), 145-153, 2005.

Yin XJ, Dong CC, Ma JYC, Antonini JM, Roberts JR, Barger MW and Ma JKH. Sustained effect of inhaled diesel exhaust parti-cles on T-lymphocyte-mediated immune responses against Listeria monocytogenes. Toxicol. Sci. 88, 73-81, 2005.


EFFECTS: ENVIRONMENT

Quistad GB, Klintenberg R, and Casida JE. Blood acylpeptide hydrolase activity is a sensitive marker for exposure to someorganophosphate toxicants. Toxicol. Sci. 86, 300-308, 2005.

GENERAL IMMUNOTOXICOLOGY

Funatake CJ, Marshall NB, Steppan LB, Mourich DV, and Kerkvliet NI. Activation of the aryl hydrocarbon receptor by 2,3,7,8-tetrachlorodibenzo-p-dioxin generates a population of CD4+CD25+ cells with characteristics of regulatory T cells. J. Immunol.175(7), 4184-4188, 2005.

Ghio AJ and Cohen MD. 2005. Disruption of iron homeostasis as a mechanism of biologic effect by particles. Inhal. Toxicol. 17,709-716, 2005.

Keller JM, Peden-Adams MM, Aguirre AA. Immunotoxicology and implications for reptilian health. In: Toxicology of Reptiles.Eds: E. Oberdörster and S. Gardner. CRC Press, Taylor and Francis Group, Boca Raton, FL. Release date October 28, 2005.

Martin PL, Jiao Q, Cornacoff J, Hall W, Saville B, Nemeth JA, Schantz A, Mata M, Jang H, Fasanmade AA, Anderson L,Graham M, Davis HM, and Treacy G. Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fullyhuman anti-alphav integrin monoclonal antibody, despite widespread tissue binding. Clin. Cancer Res. 11, 6959, 2005.

Nierkens S, Bleumink R, Bol M, Hassing I, van Rooijen N, Pieters R. The reactive d-glucopyranose moiety of Streptozotocin isresponsible for activation of macrophages and subsequent stimulation of CD8+ T cells. Chem. Res. Toxicol. 18, 872-879, 2005.

Nierkens S, Aalbers M, Bleumink R, Boon L, and Pieters R. Drug-induced type 1 and type 2 immune responses are character-ized by distinct profiles of cell kinetics, cytokine production, and expression of co-stimulatory molecules in the popliteal lymphnode assay. J. Immunotoxicol. 2, 141-150, 2005.

t’Hart BA, Brok HP, Benson J, Treacy G, Laman J, Bauer J, and Blezer, E. Suppression of ongoing disease in a non-human pri-mate model of multiple sclerosis by a human anti-human IL-12p40 antibody. J. Immunol. 175, 4761-4768, 2005.

Ulrich P, and Nakamura K. Development of the ICH guidelines for immunotoxicology evaluation of pharmaceuticals using asurvey of industry practices. J. Immunotoxicol. 2, 171-180, 2005.

Weaver JL, Tsutsui N, Hisada S, Vidal JM, Spanhaak S, Sawada J, Hastings KL, van der Laan JW, van Loveren H, KawabataTT, Sims JR, Durham SK, Fueki O, Matula TI, Kusunoki HI, Ulrich P and Nakamura K.

Development of the ICH guidelines for immunotoxicology evaluation of pharmaceuticals using a survey of industry practices. J.Immunotoxicol. 2, 171-180, 2005.

ReviewsLadics GS, and Loveless SE. Commentary on hormetic dose-response relationships in immunology: occurrence, quantitativefeatures of the dose response, mechanistic foundations, and clinical implications. Crit. Rev. Toxicol. 35:1-2, 2005.

GENETICS AND IMMUNOLOGY

Currie RA, Bombail V, Oliver JD, Moore DJ, Lim FL, Gwilliam V, Kimber I, Chipman K, Moggs JG and Orphanides G. Geneontology mapping as an unbiased method for identifying molecular pathways and processes affected by toxicant exposure: appli-cation of acute effects caused by the rodent non-genotoxic carcinogen diethylhexylphthalate. Toxiocol. Sci. 86, 453-469, 2005.

Moggs JG, Murphy TC, Lim FL, Moore DJ, Stuckey R, Antrobus K, Kimber I and Orphanides G. Anti-proliferative effect ofestrogen in breast cancer cells that re-express ER? is mediated by aberrant regulation of cell cycle genes. J. Mol. Endocrinol. 34,535-551, 2005.

ReviewsAalberse RC. Assessment of sequence homology and cross-reactivity. Toxicol. Appl. Pharmacol. 207 (2), (1 Suppl.), 149-151,2005.



MODELS AND METHODS

Basketter DA, Anderson KE, Liden C, Van Loveren H, Boman A, Kimber I, Alanko K and Berggren E. Evaluation of skin sensi-tizing potency of chemicals by using the existing methods and considerations of relevance for elicitation. Contact Derm. 52, 39-43, 2005.

Casati S, Aeby P, Basketter DA, Cavani A, Gennari A, Gerberick GF, Griem P, Hartung T, Kimber I, Lepoittevin JP, Meade BJ,Pallardy M, Rougier N, Rousset F, Rubinstenn G, Sallusto F, Verheyen GR and Zuang V. Dendritic cells as a tool for the predic-tive identification of skin sensitisation hazard. Altern. Lab. Anim. 33, 47-62, 2005.

Furst SM, Nasir Khan K, Komocsar WJ, Fan L, and Mennear J. Screening new drugs for immunotoxic potential: II. Assessmentof the effects of selective and nonselective COX-2 inhibitors on complement activation, superoxide anion production and leuko-cyte chemotaxis and migration through endothelial cells. J. Immunotoxicol. 2, 85-96, 2005.

Furst SM, Komocsar WJ, Mennear J, and Nasir Khan K. Screening new drugs for immunotoxic potential: III. Assessment of theeffects of selective and nonselective COX-2 inhibitors on T-cell-dependent antibody and natural killer cell responses in the rat. J.Immunotoxicol. 2, 161-170, 2005.

Gennari A, Ban M, Braun A, Casati S, Corsini E, Dastych J, Descotes J, Hartung T, Hooghe-Peters R, House R, Pallardy M,Pieters R, Reid L, Tryphonas H, Tschirhart E, Tuschl H, Vandebriel R, and Gribaldo L. The use of in vitro systems for evaluatingimmunotoxicity. The report and recommendations of ECVAM Workshop. J. Immunotox. 2, 61-83, 2005.

Nierkens S, Aalbers M, Bol M, Hassing I, and Pieters R. Development of an oral exposure mouse model to predict drug-inducedhypersensitivity reactions by using reporter antigens. Toxicol. Sci. 83, 273-281, 2005.

ReviewsNierkens S, Pieters R. Murine models of drug hypersensitivity. Curr. Opin. Allergy Clin. Immunol. 5, 331-335, 2005.

Trzaska D, Zembek P, Olszewski M, Adamczewska V, Ulleras E and Dastych J. “Fluorescent Cell Chip” for immunotoxicitytesting: Development of the c-fos expression reporter cell lines. Toxicol. Appl. Pharmacol. 207 (2) (1 Suppl.), 133-141, 2005.

Vandebriel RJ, Van Och FMM and van Loveren H. In vitro assessment of sensitizing activity of low molecular weight com-pounds. Toxicol. Appl. Pharmacol. 207 (2), (1 Suppl.), 142-148, 2005.

SAFETY/RISK ASSESSMENT

Rider CV and LeBlanc GA. An integrated addition and interaction model for assessing toxicity of chemical mixtures. Toxicol.Sci. 87, 520-528, 2005.

Silkworth JB, Koganti A, Illouz K, Possolo A, Zhao M and Hamilton SB. Comparison of TCDD and PCB CYP1A1 inductionsensitivities in fresh hepatocytes from human donors, Sprague-Dawley rats and Rhesus monkeys and HepG2 cells. Toxicol. Sci.87, 508-519, 2005.

Documents

Immunotoxicology Specialty Section Newsletter · Immunotoxicology Specialty Section Newsletter President Dr. Kenneth L. Hastings Vice President Dr. Mitchell D. Cohen Vice President-Elect